A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

A

Agouron Pharmaceuticals

Status and phase

Completed
Phase 2

Conditions

Mycobacterium Avium-Intracellulare Infection
HIV Infections

Treatments

Drug: Nelfinavir mesylate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002170
Study 518
259C
AG1343-518

Details and patient eligibility

About

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.

Sex

All

Ages

13+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

  • HIV infection
  • New diagnosis of MAC bacteremia and < 7 days of therapy.

Prior Medication:

Allowed:

Patients no more than 7 days of therapy for MAC disease.

Exclusion Criteria

Prior Medication:

Excluded:

Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems